← All trials
NCT03704363
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 12, 2018
- Primary completion
- May 31, 2021
- Completion date
- Oct 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 126
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OsloLead sponsor
- University of OsloOverall official - principal investigator
- University of OsloReponsible party - principal investigator
- University of OsloStudy chair
- Vestre Viken Ringerike SykehusCollaborator
- Norwegian University of Science and TechnologyCollaborator
- University Hospital of North NorwayCollaborator
- Diakonhjemmet HospitalCollaborator
- University of BergenCollaborator
- University of BergenOverall official - principal investigator
- Vestre Viken Ringerike SykehusOverall official - principal investigator
- University Hospital of North NorwayOverall official - principal investigator
- St. Olav University Hospital, NorwayOverall official - principal investigator
- South-Eastern Norway Regional Health AuthorityCollaborator
- South-Eastern Norway Regional Health AuthorityOverall official - principal investigator
- Oslo Metropolitan UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.